Search
Choline C 11
go.drugbank.com/drugs/DB09277Approved[A32041] It was developed by MCPRF and FDA first approved in September 2012.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalAsparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia
Synonyms: Asparaginase (E. coli), E. coli AsparaginaseProducts: LEUNASE FOR INJECTION 10,000 iu/vial, LEUNASE ENJEKTABL 10.000 IU FLAKON, 1 ADETMarstacimab
go.drugbank.com/drugs/DB17725ApprovedInvestigationalMarstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology. It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anti...
Homatropine
go.drugbank.com/drugs/DB11181Approvedadministered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA
Aluminum zirconium trichlorohydrex gly
go.drugbank.com/drugs/DB11116ApprovedWithdrawnAluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalThe FDA said it is keeping the black box in place at least until the results of the trial are announced.
Mixtures: Nra-varenicline, Nra-vareniclineProducts: Nra-vareniclineLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalCasimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent